31JUL

Cytospire's £61m oncology Series A oversubscribed

3 min read

12:32UTC

Cytospire Therapeutics, a London biotech incorporated in February 2023, closed an oversubscribed £61m Series A on 5 May with the British Business Bank contributing £12m alongside international specialist funds.

← Back to Humanoid hit $1.35bn on a customer order Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Cytospire's oversubscribed £61m Series A at under three years old shows UK oncology attracts specialist international capital pre-clinical.

Cytospire Therapeutics, a London biotech incorporated in February 2023, closed an oversubscribed £61m Series A on 5 May 2026. 4BIO Capital led the round; Servier Ventures, Abingworth, LifeArc Ventures, Sound Bioventures, and Medical Incubator Japan participated. The British Business Bank (BBB) contributed £12m, drawing on the direct-investment mandate that activated in April 2026, the same instrument behind the £40m Quantum Motion cornerstone . ¹

Cytospire's lead programme, CYT X300, is a first-in-class pan-gamma delta T cell engager targeting EGFR (Epidermal Growth Factor Receptor)-positive solid tumours. Existing cancer immunotherapy approaches typically target specific gamma delta T cell subtypes; CYT X300 targets all subtypes simultaneously, which is the mechanism the company claims distinguishes it clinically. Funds from the Series A go toward IND-enabling (Investigational New Drug) studies and Good Manufacturing Practice (GMP) manufacturing ahead of a first-in-human trial.

CellCentric closed its Series D on the same day, drawing exclusively private institutional capital from US and European healthcare funds, plus Pfizer as a strategic participant; Cytospire drew the BBB as a public co-investor alongside international specialist biotech funds. Two UK oncology rounds, one calendar day, two entirely different capital structures. The DSIT Life Sciences Innovative Manufacturing Fund had already allocated over £80m to four regional manufacturing sites on 14 April , signalling that DSIT-adjacent capital is entering life sciences at multiple points along the development chain. The BBB's presence in a sub-£100m Series A where private capital was already oversubscribing raises the additionality question the mandate was supposed to address: the fund is entering rounds where demand already exceeds supply, not rounds where private capital has declined to participate.

For UK oncology founders, the data point is the oversubscription at less than three years from incorporation: a first-in-class mechanism, no clinical data yet, and specialist international co-investors willing to lead. The BBB's £12m did not anchor the round; 4BIO Capital led it.

Deep Analysis

In plain English

Cytospire has developed a cancer treatment that works by recruiting a type of immune cell called gamma delta T cells to attack tumours. Existing cancer immunotherapies target specific subtypes of these cells; Cytospire's drug, CYT X300, is designed to engage all of them at once, potentially treating a wider range of patients with EGFR-positive solid tumours, a category that includes some lung, colorectal, and head and neck cancers. The company raised £61m in May 2026, just over three years after it was founded in London. The British Business Bank put in £12m alongside specialist cancer investment funds from the UK, France, Japan, and the US. The money funds safety testing studies and manufacturing preparation before the first clinical trial in humans.

Deep Analysis

Root Causes

The BBB's £12m contribution to an oversubscribed Series A illustrates the additionality question embedded in the new mandate.

Private capital led by 4BIO Capital and backed by Servier Ventures, Abingworth, and LifeArc Ventures had already pushed the round past its target. The BBB entered a round where private institutional appetite exceeded supply, which is the opposite of the seed-gap market failure the mandate was designed to address.

What could happen next?

Opportunity
Cytospire's international syndicate including Medical Incubator Japan positions the company for early Asian licensing discussions, a capital-efficient route to funding Phase 1 without requiring a US listing.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: The 2016 to 2019 wave of UK CAR-T (chimeric antigen receptor T cell) companies, including Autolus Therapeutics (UCL spinout, listed on Nasdaq 2018), showed that British academic immunotherapy programmes can attract international Series A capital before clinical proof of concept when the mechanism is genuinely first-in-class.

Autolus raised £120m in its 2018 IPO on the strength of preclinical and Phase 1 data. Cytospire is following the same pattern at the same stage with a different T cell modality.

Counter-parallel: Kymera Therapeutics, a Boston immunotherapy company, raised $102m in a 2021 Series C on targeted protein degradation; its lead programme entered Phase 2 in 2023 but produced a clinical hold in 2024. First-in-class mechanism does not guarantee clinical success, and Cytospire's IND-enabling stage means investors are pricing in a multi-year clinical risk period with no human safety data yet.

At £61m Series A for a company incorporated in February 2023, Cytospire's implied post-money valuation positions it at the upper end of preclinical UK biotech, consistent with first-in-class mechanism pricing by specialist institutional funds.

The Japanese co-investor Medical Incubator Japan signals that Asian pharma groups are monitoring UK oncology immunotherapy for licensing optionality, which compresses the timeline to a potential non-dilutive licensing deal alongside the clinical programme.

Consensus view: 4BIO Capital's managing partners assess pan-gamma delta T cell engagers as a clinically distinct approach to solid tumour immunotherapy: unlike checkpoint inhibitors (pembrolizumab, nivolumab) which release existing T cell activity, CYT X300 recruits gamma delta T cells as effectors across the full heterogeneous population of EGFR-positive tumour subtypes.

The oversubscription at less than three years from incorporation reflects specialist investors pricing clinical optionality before Phase 1 data.

Counter-view: The Francis Crick Institute's immunology group notes that pan-gamma delta engagement has produced cytokine release syndrome in preclinical models. First-in-human trial design will require careful dose-escalation protocols, and the IND-enabling stage that Cytospire is funding carries significant safety risk before efficacy data exist.

Key tension: Whether pan-gamma delta T cell engagement can maintain tumour selectivity across heterogeneous patient populations without triggering systemic immune responses that limit the therapeutic window.

First Reported In

Update #4 · State capital lands on UK tech in nine days

BioSpace (via GlobeNewswire)· 13 May 2026

Read original →

Causes and effects

Caused by

Business Bank begins direct startup investment

The BBB's £12m Cytospire co-investment is direct-mandate capital under the £6.6bn expansion activated in April 2026 (ID:2343).

Occurred 6 Apr 2026

Read story →

This Event

Cytospire's £61m oncology Series A oversubscribed

Cytospire's oversubscribed round at less than three years old shows that UK oncology immunotherapy companies with first-in-class mechanisms can attract large Series A rounds from international specialist capital, with public co-investment from the BBB entering rounds where private institutional appetite is already present.

Led to

State £50m backs the tier funds skip

The BBB's £12m into Cytospire (ID:3277) is part of the same £6.6bn direct mandate deployment that backstops Longwall Fund 4.

Occurred 27 May 2026

Read story →

IMU raises £40m to read blood

BBB's £12m co-investment in Cytospire's Series A in May established the direct BBB biotech co-investor pattern repeated in IMU Biosciences.

Occurred 2 Jun 2026

Read story →

Different Perspectives

Fubon Financial

Fubon Financial joined Humanoid's Series A on 21 July as a minority financial investor alongside Schaeffler and Bosch, who also hold the customer and manufacturer roles. A pure-play investor from Taipei is pricing a London robot maker on terms two German industrial groups effectively set.

NATO Innovation Fund

The Fund joined Greenjets' £30m Series A on 21 July alongside NSSIF, betting on ducted electric propulsion's civil market to fund a technology with an obvious defence application. It is backing a company that took twenty-one years to reach this stage, on the expectation that certification-cycle timelines reward patient capital over a quick return.

Prime Movers Lab

Prime Movers Lab led Humanoid's Series A on 21 July as the round's only pure financial investor, sharing the cap table with two co-investors who are also the anchor customer and the factory. That leaves the fund's usual arm's-length pricing role diluted by partners with a direct commercial stake in the valuation holding up.

Bosch and Schaeffler

Schaeffler signed what Humanoid calls the industry's largest publicly announced commercial agreement, while Bosch took equity and became contract manufacturer, filling capacity a shrinking combustion supply chain freed. Neither company has disclosed a unit count or an invoice, so their public commitment stops well short of Forbes' 100,000-unit projection.

UK founders raising seed through Series A

A London robotics founder raised $152m this week against a signed industrial customer and a reserved factory, while a Cornwall founder more typically draws a £25,000 loan from a regional fund manager. Both call it British venture funding, but one route runs through Bosch's production line and the other through diligence built for businesses too small for any VC's attention.

EQT

EQT was reported on 3 July to be in advanced talks for a further CuspAI stake on behalf of the EU's Scaleup Europe Fund, but does not appear on the round CuspAI closed. Whether Europe's own sovereign vehicle secured a position, was outbid, or withdrew is unresolved.